Company presentation – Full year 2016












SOL Group at a glance

- Founded in 1927, is an Italian based multinational company present in 28 countries with more of 3,200 people employed.
- Two core, separated but integrated and synergic business areas: Technical Gas sector (production, applied research and marketing of pure, medical and industrial gases) and Home-Care service sector (supply of medical products and medical assistance services as well as equipment for home care therapy).
- Two recent businesses: Hydro Energy and Biotechnology.
- Strong results and sound balance sheet:
 - Over 703 millions € of Total Group revenues in FY2016 (+4.3% FY2015);
 - Over 52% of international revenues in 2016 (vs 23.7% in 2000)
 - 6.0% sales CAGR in the last 10 years;
 - 23.8% of EBITDA margin in 2016;
 - 0.473 of Debt/Equity ratio;
 - Dividend policy: 29% average dividend pay out ratio over the last 10 years.



SOL Group – Geographic Presence



The Technical Gases Business





The Technical Gases Business

SOL Group operates in the technical gases business throughout the brand SOL

Production and distribution of Gases

A complete range of industrial gas (both atmospheric and non-atmospheric): medicinal, pure and special gases.

- Oxygen
- Nitrogen
- Argon
- Hydrogen
- Carbon dioxide
- Acetylene
- Nitrous oxide
- Gas mixtures

- Ultra high purity gases
- Medical gases
- Gaseous helium
- Liquid helium
- Refrigerating gases
- Electronics gases
- Ammonia
- Combustible gases

Supply of plants, equipments, services and consultancy

Research, design, and construction of:

- Industrial gas production facilities,
- Plant and equipment for gas utilization
- Services and consultancy

- Equipment for medical applications
- Equipment for cryogenic applications
- Deep freezing tunnels
- Oxygen burners
- Ozonisers

- Medical air plants
- On-site plants
- Welding machines and equipment




Technical Gases Business


Technical gases business (M€)	FY2016	FY2015	YoY
Sales	373	364	+ 2.6%
EBITDA	76	68	+ 12.2%
EBITDA %	20.3%	18.6%	+ 1.7%
Investments	57	46	+ 25.0%

- In 2016 the division invested over the
 15% of its revenues.
- . 2.8% sales CAGR over the last 10 ys.

SOL Group 2016 Total revenues









Technical Gases business

Market characteristics

- · Resilient and growing market
- Margin protected thanks to high entry barriers
- Limited economic cycle demand dependence of each sales area
 - Broad variety and diversification of end-markets and applications
- Medium/long term contracts
- Local presence as a key factor

SOL

- · High diversification of sales area:
 - · More than 50,000 clients served;
 - More than 90 different applications for technical gases
- . Long term contracts with customers:
 - Gas pipeline: up to 15 years;
 - Compressed gases: up to 5 years;
 - Cryogenic liquid gases: up to 3 years
- Strong local presence:
 - 25 countries, 38 primary transformation plants, 56 secondary transformation plants.




Resilience + Growth + Demand stability + Low risk level


Technical Gases Business

Specialty and medicinal gases and services

- The uses of specialty gases are expanding in many different context. The market need for maximum accuracy finds its answer in the world of gases:
 - Universities and research centers: highly purified gas carriers for gas chromatography, calibration equipment and gaseous compounds used as precursors for chemical synthesis;
 - Chemical and pharmaceutical carrier gases and calibration gases in many activities related to process control;
 - Hospitals: medicinal gases for pharmaceutical use, pure products and mixtures for laboratory and analytical activities as a support to diagnostic processes, cryomangement services;
 - High-tech industry sectors (such as electronics, automotive and renewable energies) where the use of gases is vital to the innovation of production processes.









The Home Care Business





The Home Care Business

- In the second half of the eighties, SOL seized a new market diversification opportunity by entering into the Home-Care service sector, synergical with the technical gas sector.
- The Group works through the VIVISOL Group, which supplies technologically advanced home care services to patients for the treatment of chronic pathologies.
- VIVISOL manages the complete patient care from the delivery of medical equipment and drugs, performed by specialized home care professionals, to the provision of qualified medical and nursing services, as well as tele-monitoring services and emergency management.
- The company operates in 12 leading countries in Europe, in Brazil and Turkey, with over 60 offices employing over 1.600 employees and serving more than 350.000 patients daily.





Home care respiratory assistance

Respiratory home-care services concern the home delivery to patients of oxygen or enriched air and other services such as ventilation, diagnosis of pulmonary pathologies and therapy of respiratory disorders.

- Long term oxygen therapy
- Mechanical ventilation therapy
- Assistance to patients undergoing oxygen therapy during travels (VIVITRAVEL)
- Diagnosis and treatment of sleep disorder conditions

Other home care assistance

The other home-care services include telemedicine services, artificial nutrition, integrated home-care service in the respiratory framework and in monitoring child respiratory disorders.

- Home care artificial nutrition
- Integrated home care services
- Remote monitoring and diagnosis of respiration conditions


Home care equipment

VIVISOL markets also equipment intended for the diagnosis and therapy of the above-mentioned pathologies and its customers include hospitals, pharmacists, laboratories, clinics and doctors.

- Home and traveling oxygen therapy equipments
- Ventilation equipment
- Instruments and accessories for diagnosis and aerosol treatment
- Home aids




Hone Care business (M€)	FY2016	FY2015	YoY
Sales	360	340	+ 5.9%
EBITDA	92	81	+ 13.7%
EBITDA %	25.5%	23.7%	+ 1.7%
Investments	41	39	+ 5.7%



- VIVISOL was able to grow 6% in 2016, with an EBITDA margin higher than 25%.
- The Group is continuing to invest significantly in this business.








Key growth drivers:

- Aging population demographics
- Restructuring of Health Care Systems through de-hospitalization and home care
- Developments in portable medical technologies
- Better quality of life for Patients at home
- Increasing of respiratory and chronic pathologies





Home Care - VIVISOL branches








The Hydro Energy Business





The Hydro Energy Business

- Leveraging on its core business development in the Eastern Europe, SOL entered into the Hydro-Energy sector.
- The industrial gas sector, is one of the most energy intensive one. This characteristic supported the Group decision to invest in the Hydro-Energy sector in order to enjoy synergies with its Industrial Gases Business.





Currently the company owns and operates 5 hydro-electric power plants in Slovenia (about 50 Million KWh/year), 2 plants in Albania (about 25 Million KWh/year); 4 plants in Macedonia (about 35 Million KWh/year); 4 plants (one is under construction) in Bosnia (about 6 Million KWh/year).



The Biotechnology Business





The Biotechnology Business


- SOL Group is active in supplying biotechnological equipment and services to hospitals, clinics and laboratories (cryobanks, cellfactories, cryomanagement, cryotransportation)
- With BIOTECHSOL is active in the area of tissue and stem cells banking and biological tissues transportation.
- With the acquisition of the majority of DIATHEVA, SOL Group is active in drug discovery and drug delivery (recombinant monoclonal antibodies), molecular diagnostic, GMP production of recombinant proteins








SOL Group: 30 years Deflated Turnover (1986-2016)







SOL Group: consolidated results (2006 – 2016)





EBITDA






10 years net profit and dividend growth

NET PROFIT

DPS - Dividend Yield



10Y AVERAGE PAY-OUT RATIO 29%



International Expansion

10 years sales outside Italy 2006-2016




SOL is focused on its international expansion:

- The Group started its operations in Italy where it currently has 15 primary production sites.
- In 2016 the Group is present in 28 countries.
- In 2016 the non-domestic sales exceeded the Italian sales
- . (52.9% / 47.1%).



Capital Expenditures (2006-2016)

10 years of investments on sales 2006-2016



High annual investments

- The Group every year invest about 15% of its revenues;
- The Sol business require a high level of investments for long term growth options;
- In 2016 almost the 50% of the Group investments was made outside Italy.



Shareholding information and market price



Source: Borsa Italiana

Outstanding Shares

- . 90.700.000 ordinary shares
- par value: 0,52

Shareholding Structure

- Fumagalli and Annoni families 60%
- . Main Institutional Investors:
 - . Tweedy Brown 7,346%
 - . J O Hambro 5,072%
 - . Allianz 5,072%













